Compare Merck & Co., Inc. (MRK) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Vanguard Total International Stock Index Fund ETF trades at $84.94 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| MRK | VXUS | |
|---|---|---|
Market Cap | $351.28B | $665.70B |
Volume | 7,969,665 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $156.43 | $88.41 |
52-Week Low | $82.49 | $72.17 |
Typical Hold Time | 98 Days | 55 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
VXUS trades at $84.82 with minimal daily movement (+0.05%), showing technical bearish signals across multiple indicators. The ETF faces selling pressure with moving averages and oscillators in bearish alignment, though RSI levels suggest potential oversold conditions. Recent news highlights VXUS as a core international diversification tool, with institutional investors increasing positions significantly during Q2 2026.
The outlook remains cautious due to technical weakness, but long-term prospects appear solid given VXUS's role in global portfolio diversification. Key risks include international market volatility and currency fluctuations, while institutional accumulation suggests confidence in international equity exposure despite near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
